Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
Liren Qian, Miao Liu, Jianliang Shen, Jian Cen, Defeng Zhao · Frontiers in immunology · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 24 patients with few side effects, the study found that among patients who continued to drink hydrogen-rich water for more than 12 months, KPS has been improved (p=0.034). These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 24 patients with few side effects. The study found that among patients who continued to drink hydrogen-rich water for more than 12 months, KPS has been improved (p=0.034).
What the Researchers Studied
The researchers studied 24 patients with few side effects. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen exposure: 4 mL hydrogen-rich water per reported dose; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂; reported treatment duration: 12 months. The study found that among patients who continued to drink hydrogen-rich water for more than 12 months, KPS has been improved (p=0.034). The authors concluded that in this study, the researchers evaluated the response rate and toxicity of molecular hydrogen on patients with chronic GVHD who are corticosteroid-refractory/dependent.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 24 patients with few side effects. The reported sample size was 24. The study used a human clinical study. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen exposure was 4 mL hydrogen-rich water per reported dose; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂. The reported treatment duration was 12 months.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.